following a resubmission assessed under the end of life and orphan medicine
process:
tebentafusp (Kimmtrak®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of human leukocyte antigen
(HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Tebentafusp improved overall survival compared with investigator’s choice of treatment, in
(HLA)-A*02:01-positive adults with unresectable or metastatic uveal melanoma.
The submitting company’s justification of the treatment’s cost in relation to its health
benefits was not sufficient and in addition the company did not present a sufficiently robust
economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE)
meeting.
Medicine details
- Medicine name:
- tebentafusp (Kimmtrak)
- SMC ID:
- SMC2746
- Indication:
Treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma.
- Pharmaceutical company
- Immunocore Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 April 2025